Financial Snapshot

Revenue

TTM

$458.0M

Gross Margin

TTM

31.26%

Net Income

TTM

-$53.81M

Current Assets

Last 4 Quarters

N/A

Current Liabilities

Last 4 Quarters

N/A

Current Ratio

Last 4 Quarters

N/A

Total Assets

2025 Q4

$690.6M

Total Liabilities

2025 Q4

$294.2M

Book Value

2025 Q4

396.4M

Cash

Last 4 Quarters

N/A

P/E

Last 4 Quarters

N/A

Free Cash Flow

TTM

-$3.023M

Stock Price

Market Cap: $164.21 Million

About InterCure Ltd

InterCure Ltd. engages in the provision of business of medical cannabis and biomedicine. Thorugh its wholly owned subsidiary Canndoc the Company operates as licensed cannabis producer and one of the first to offer Good Manufacturing Practices (GMP) certified and pharmaceutical-grade medical cannabis products.

Industry: Pharmaceutical Preparations Peers: Mediwound Ltd Sol Gel Technologies Ltd TARO PHARMACEUTICAL INDUSTRIES LTD